Comparative Pharmacology
Head-to-head clinical analysis: AMOXICILLIN CLAVULANATE versus AMPICILLIN TRIHYDRATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMOXICILLIN CLAVULANATE versus AMPICILLIN TRIHYDRATE.
Amoxicillin-Clavulanate vs AMPICILLIN TRIHYDRATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and autolysin inhibitors. Clavulanate is a beta-lactamase inhibitor that binds to and inactivates beta-lactamases, protecting amoxicillin from hydrolysis.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and autolysin activity.
500 mg/125 mg orally every 8 hours or 875 mg/125 mg orally every 12 hours; intravenous: 1 g/0.2 g every 8 hours.
250-500 mg PO q6h or 1-2 g IV/IM q4-6h; up to 12 g/day IV for severe infections.
None Documented
None Documented
Amoxicillin: ~1-1.3 hours in adults with normal renal function; Clavulanate: ~1 hour. Both prolonged in renal impairment (amoxicillin up to 7-20 hours with CrCl <10 mL/min).
Terminal elimination half-life 1-1.8 hours; prolonged in renal impairment (up to 10-20 hours in anuria)
Amoxicillin: ~60% renal as unchanged drug via glomerular filtration and tubular secretion; Clavulanate: ~30-50% renal as metabolites and unchanged, remainder fecal. Approximately 50-70% of total dose excreted renally within 6 hours.
Renal: 75-90% unchanged; biliary: small amount; fecal: negligible
Category C
Category A/B
Penicillin Antibiotic + Beta-Lactamase Inhibitor
Penicillin Antibiotic